Sanofi, tolebrutinib
Tolebrutinib Slows Disability in Non-Relapsing Secondary Progressive MS
Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's tyrosine kinase (BTK) inhibitor met the study's primary endpoint of delaying time to onset of 6-month confirmed disability progression (CDP),
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
Sanofi's tolebrutinib cuts MS progression by 31% in trial
Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was able to delay the time to six-month disability progression by 31% compared to placebo in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS).
Sanofi’s Tolebrutinib Delays MS Progression in Phase III Study Following Earlier Flops
The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of back-to-back failures in which tolebrutinib was unable to improve relapse rates in patients with relapsing MS.
Sanofi says tolebrutinib drug delayed progressive MS by 31%
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows
Sanofi SA (NASDAQ:SNY) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive multiple sclerosis (nrSPMS). The data demonstrated that tolebrutinib delayed the time to onset of 6-month confirmed disability progression (CDP) by 31% compared to placebo (HR 0.
Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression
Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.
Sanofi’s eyes approval after MS therapy slows disease progression by 31%
After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS patients.
FierceBiotech1d
Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings
Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...
BioWorld2d
MS Aubagio tableau: Sanofi talks tolebrutinib, Immunic the pick?
The specter of elevated liver enzymes, a known problem with the drug class, became a topic of talk with regard to Sanofi SA’s ...
Medscape1d
Novel Agent First to Slow Disability in Nonrelapsing Secondary MS
The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.
Monthly Prescribing Reference17d
Tolebrutinib Looks Promising for Patients With Non-Relapsing Secondary Progressive MS
Tolebrutinib was found to delay disability progression in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS), according to results from the HERCULES study.
BioWorld19d
Sanofi BTK inhibitor tolebrutinib hits phase III endpoints in MS
Sanofi SA’s brain-penetrant Bruton's tyrosine kinase (BTK) inhibitor, tolebrutinib, met the primary endpoint in the phase III Hercules trial in non-relapsing secondary progressive multiple sclerosis ...
MarketWatch19d
Sanofi: Tolebrutinib Meets Primary Endpoint in Phase 3 Study
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...